Researchers review iPSC-based modeling of neurodegeneration and the challenge of epigenetic erasure

A newly published review in the Journal of Clinical Investigation highlights how standard iPSC reprogramming erases epigenetic aging signatures, limiting the modeling of late-onset neurodegeneration, and discusses direct conversion strategies as a viable alternative.

A scientific review published in the Journal of Clinical Investigation explored the opportunities, limitations, and the challenge of aging in iPSC-based models of human neurodegeneration.

The authors reported that Phase III clinical trial failure rates for neurodegenerative indications exceed 95%, which they attribute in part to the limitations of existing preclinical models in recapitulating the complex human genetic and age-dependent context.

The review notes that standard iPSC reprogramming erases epigenetic signatures of donor aging, eliminating the cellular context in which late-onset sporadic neurodegeneration emerges.

The authors discussed current corrective strategies, including direct conversion protocols that bypass pluripotency to preserve the donor's native epigenetic age, thus enabling the observation of age-dependent phenotypes in vitro.

The current high failure rate of Phase III trials in neurodegeneration underscores the need for preclinical models that accurately maintain the aging context of human cells.

By stripping away the epigenetic history of donor cells, traditional iPSC models may fail to replicate sporadic, late-onset disease biology that depends heavily on aging factors.

Direct conversion and artificial aging strategies represent important methodological shifts to ensure that preclinical testing matches the biological context of elderly patients.

The development and validation of direct conversion techniques could alter how preclinical research is conducted across the biopharmaceutical industry, particularly for companies targeting late-onset neurodegenerative diseases.

Preclinical pipelines reliant on standard iPSC reprogramming may face pressure to adopt direct conversion or age-approximation tools to improve clinical translation and mitigate historical Phase III failure risks.

The integration of direct conversion technologies and epigenetic age-approximation tools into early-stage discovery pipelines for neurodegenerative therapeutics.